Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK ( TheStreet) -- What was the real cause for today's rally on Wall Street? Was it anticipation over the European Central Bank making all the right moves, or the U.S. Federal Reserve raising interest rates? None of the above, Jim Cramer told his Mad Money TV show viewers. Cramer said today's rally was all about investors binge buying  Netflix ( NFLX - Get Report) .

It may seem ridiculous to think a single stock has the power to move the markets, Cramer continued, but in the case of Netflix it may actually be true. Netflix is a "cult stock," one that doesn't trade on revenue or earnings but rather its latest subscriber growth or rumors of its newest hit series.

When shares of Netflix get moving, they can take the other cult stocks along for the ride, stocks including Tesla Motors (TSLA - Get Report) , Amazon.com (AMZN - Get Report) and Priceline.com (PCLN) . Even GoPro (GPRO - Get Report) , which has been struggling of late, managed a $3-a-share rally.

Cramer noted that tech component makers Skyworks Solutions (SWKS - Get Report) and SanDisk (SNDK) also rallied on the day, as did Unitedhealth Group (UNH - Get Report) , a Cramer fave.

Not all stocks ended the day higher, Cramer said -- look at IBM (IBM - Get Report) . But when the momentum stocks get rolling, that's how a rally is born.

Executive Decision: John Crowley

For his "Executive Decision" segment, Cramer sat down with John Crowley, chairman and CEO of Amicus Therapeutics (FOLD - Get Report) , a biotech company pioneering new treatments for Pompe disease, a muscular disorder, among other rare and orphan diseases.

Crowley explained that his own daughters suffer from Pompe and were the inspiration behind the movie Extraordinary Measures, starring Harrison Ford, that debuted five years ago. Crowley said the first-generation treatment featured in the movie helped save his daughters' lives, but now Amicus is working on the next generation of therapies to take their extraordinary science to the next level.

Crowley said Amicus wants to develop new treatments as well as improve on existing ones, such as converting injection treatments into pill forms that are easier for patients to manage. The company is also working on new therapies for Fabry disease, another rare condition.

Cramer commended for Crowley's passion and courage in helping patients lead better lives.

Hail, Netflix

Sometimes it's hard, or even impossible, to spot a company that's doing well before it actually tells you that it's doing well. But in the case of Netflix, Cramer said both management and a few key analysts saw the company's strength, and for that they deserve a "job well done."

Cramer said both management and analysts have practically been urging investors to buy Netflix because the company's original content is not only proving to be cheaper than traditional content but it's driving more viewers to the service.

Netflix is gaining pricing power, Cramer noted. Customers are increasingly willing to pay more for a service they're watching more.

Cramer said everyone wins with Netflix. Management is doing a terrific job delivering on their promises and the analysts are actually getting it right, giving investors actionable insights.

Executive Decision: Michael Weiss

In his second "Executive Decision" segment, Cramer also sat down with Michael Weiss, executive chairman, president and CEO of TG Therapeutics (TGTX) , another biotech company, this one working on improving blood cancer therapies. Shares of TG are down 10% over the past month after quadrupling in 2014.

Weiss explained that TG's two drugs under development are engineered to do two things -- reduce toxicity and improve potency. For example, in the case of its drug TG-1101, the company has managed to improve an existing drug, making it 50 to 100 times more potent.

Ultimately, Weiss said, TG's goal is to remove chemotherapy from cancer treatments, as chemo only makes patients sicker in many cases. He said the biotech industry is getting closer to this goal, treating cancers like they do HIV, with a cocktail of different drugs that work together and have and better results.

Cramer said that TG Therapeutics is an attractive stock given its recent pullback in price.

Lightning Round

In the Lightning Round, Cramer was bullish on Horizon Pharma (HZNP - Get Report) , Southwest Airlines (LUV - Get Report) , Carrizo Oil & Gas (CRZO - Get Report) , Cimarex Energy (XEC - Get Report) , Old Dominion Freight Line (ODFL - Get Report) , Deckers Brands (DECK) , Sprint (S - Get Report) and Cypress Semiconductor (CY - Get Report) .

Cramer was bearish on CVR Refining (CVRR) , SeaDrill Limited (SDRL - Get Report) , Rice Energy (RICE) , Greenbrier Companies (GBX - Get Report) , Castlight Health (CSLT - Get Report) and Integrated Device Technology (IDTI) .

Am I Diversified?

In the "Am I Diversified?" segment, Cramer spoke with callers and responded to tweets sent via Twitter to @JimCramer to see if investors' portfolios have what it takes for today's markets.

The first portfolio included Apple (AAPL - Get Report) , J.C. Penney (JCP - Get Report) , Time Warner (TWX) , Enterprise Product Partners (EPD - Get Report) and Under Armour (UA - Get Report) .

Cramer said he'd swap out of J.C. Penney, as it's too similar to Under Armour, and add a drug stock like his perennial fave Bristol-Myers Squibb (BMY - Get Report) .

The second portfolio's top holdings included 3M (MMM - Get Report) , Johnson & Johnson (JNJ - Get Report) , Kimberly-Clark (KMB - Get Report) , McDonald's (MCD - Get Report) and Procter & Gamble (PG - Get Report) .

Cramer said he'd sell Procter and add Walt Disney (DIS - Get Report) to properly diversify this portfolio.

The third portfolio had Apple, Alibaba (BABA - Get Report) , Altria (MO - Get Report) , Union Pacific (UNP - Get Report) and Southwest Airlines as its top five stocks.

Cramer blessed this portfolio as properly diversified.

The fourth portfolio's top stocks were Agenus (AGEN - Get Report) , Blackstone Group (BX - Get Report) , Jack Henry & Associates (JXHY) , Dominion Resources (D - Get Report) and 3M.

Cramer said he was also a fan of this diversified portfolio.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

-- Written by Scott Rutt in Washington, D.C.

To email Scott about this article, click here: Scott Rutt

Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC

At the time of publication, Cramer's Action Alerts PLUS had a position in AAPL, JNJ and MCD.